BPC-157 TB-500 is a two-peptide tissue-repair blend studied, so far, only in animal models.

Two peptides, set down as two specimen plates

BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides, sold and discussed under the name Wolverine. This reading-room keeps it the way a careful apothecary would keep a formulary entry: two specimens drawn on their own plates, each annotated to its own studies, with the join between them noted honestly rather than smoothed over.

The first specimen is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV), molecular weight ~1419.53 Da, derived from a protein found in human gastric juice. Its role in the pairing is the local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway ^[2].

The second specimen is TB-500, a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, molecular weight ~889.02 Da, corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4. Its role is the cytoskeletal signal: the LKKTETQ motif binds monomeric G-actin and regulates the actin dynamics that drive cell migration ^[3]. One caveat belongs on the plate from the start: most efficacy data filed under the name TB-500 were generated with full-length Thymosin Beta-4, a far larger molecule than the heptapeptide actually in the vial ^[5].

The rest of this record follows those two plates. The BPC-157 and TB-500 benefits for tendon and tissue recovery page keeps the repair findings; the combination rationale and synergy claim reads the two mechanisms together; the BPC-157 TB-500 dosage in the research literature keeps the research-context dose figures and the half-life and reconstitution of the blend; and the Wolverine legal status and FDA 503A compounding access page keeps the regulatory record. For the short answers, see the frequently asked questions about the blend.

What the Wolverine peptide blend is

The Wolverine peptide blend is a research-community name for the two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product. It has no single molecular weight, no CAS number, and no standardized composition — commercial vials commonly print a combined per-vial mass, for example 10 mg BPC-157 with 10 mg TB-500, but no ratio is clinically validated.

The value of treating it as two specimens rather than one product is that the evidence sorts cleanly that way. BPC-157 has its own animal-model literature; Thymosin Beta-4, the parent of the TB-500 fragment, has its own. The blend inherits both — and inherits both of their gaps.

BPC 157 TB 500 at a glance {#bpc-157-tb-500-at-a-glance}

BPC 157 TB 500 is the unhyphenated surface form of the same blend, and the chemistry does not change with the punctuation. BPC-157 stays the ~1419.53 Da pentadecapeptide; TB-500 stays the ~889.02 Da Ac-LKKTETQ heptapeptide. Both are supplied as lyophilized powders for research use, both are studied predominantly in rodents, and both are prohibited by the World Anti-Doping Agency. Neither is an FDA-approved drug, and the combination has never been tested in a controlled human trial ^[7].

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. The consolidated Thymosin Beta-4 literature is one of its two evidence sources ^[4].

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid pentadecapeptide (~1419.53 Da) derived from a gastric-juice protein, acting via VEGFR2-Akt-eNOS angiogenic signaling ^[2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889.02 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration ^[3]. They differ in structure, size, and mechanism.

BPC-157 and TB-500: the two peptides in the Wolverine blend

BPC-157 and TB-500 are paired on a complementary-mechanism rationale: BPC-157 supplies a local, vessel-facing signal, while TB-500 supplies an intracellular, cytoskeleton-facing signal. The two are described as acting through largely non-overlapping pathways, which is the basis of the marketed synergy claim.

The separate halves are genuinely characterized. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and in vitro reversed growth inhibition of tendocytes into stimulation ^[1]. Thymosin Beta-4, TB-500's parent protein, binds actin, promotes cell migration and stem-cell activity, decreases scar-forming myofibroblasts, and promotes angiogenesis ^[4].

The join is the part that is not characterized. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together ^[7]. On these plates, each specimen is drawn fully; the line connecting them into a combined effect is the warm-margin note that says "not yet measured."

Using BPC-157 with TB-500 in research models {#bpc-157-with-tb-500}

BPC-157 with TB-500 is the pairing read as a research-model construct rather than a validated combination. The rationale is that a pro-angiogenic, cytoprotective signal ^[2] plus an actin-sequestration, pro-migration signal ^[3] would cover more of the repair cascade than either alone. That logic is reasonable on paper, but it remains an extrapolation from two independently studied mechanisms — no controlled head-to-head or combination study has tested it ^[7]. The 2025 systematic review of BPC-157 in orthopaedic sports medicine makes no mention of TB-500 or combination use at all ^[7].

The Wolverine 'stack' framing {#bpc-157-tb-500-stack}

The BPC-157 TB-500 stack is the same pairing under the community term stack — a label, not an approved formulation. Commercial Wolverine vials are often labeled with a combined per-vial mass, for example 10 mg BPC-157 with 10 mg TB-500, but no standardized composition or ratio is clinically validated, and product identity and purity in unregulated material are not guaranteed. The stack inherits each component's evidence and each component's gaps.

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms — BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies an actin-sequestration and cell-migration signal — but this synergy is a theoretical extrapolation, not a finding from a controlled combination study ^[7]. The two pathways are largely non-overlapping ^{[2] [3]}.

What the blend is used for in research

In animal models, the two constituents are studied separately for tissue repair. The BPC-157 work centers on tendon, ligament, and muscle ^[1]; the TB-500 / Thymosin Beta-4 work centers on cell migration, wound re-epithelialization, reduced scarring, and angiogenesis ^[4]. Every one of those is a single-component result in a non-human model. None is a combination result, and none is a human result for the blend.

That distinction is the whole reason this reading-room keeps two plates instead of one panel. The benefits attributed to the Wolverine blend are the sum of two separate animal-model literatures, presented together, with the join drawn as an open question ^[7]. The research page reads the two mechanisms in full and keeps human clinical evidence and the data gap in plain view.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (the cytoprotective and angiogenic component); TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4 (the cytoskeletal and cell-migration component) ^[3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug.

What is the BPC-157 and TB-500 blend used for in research?

In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair ^{[1] [4]}. All efficacy data are preclinical and single-compound, not from the blend in humans — there is no controlled combination study of any kind ^[7].